Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Telix Urology Innovation Showcase to be held at The Yale Club, New York City 2023-06-21 06:31
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion 2023-06-19 08:16
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer 2023-06-15 19:00
Telix Opens European Radiopharmaceutical Production Facility 2023-06-08 20:00
Telix to Present at Jefferies Healthcare Conference 2023-06-06 08:40
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology 2023-05-25 19:00
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study 2023-05-08 05:00
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites 2023-05-08 05:00
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide 2023-05-02 05:00
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller 2023-05-01 08:58
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid 2023-04-27 06:50
Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter 2023-04-17 18:15
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical 2023-04-17 06:38
Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate 2023-04-11 05:00
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy 2023-03-16 20:28
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy 2023-03-16 08:28
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU 2023-03-14 05:11
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU 2023-03-09 04:51
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive 2023-02-27 14:37
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU 2023-02-20 07:10
1 2 3 4 5 6 7